Homology Medicines Inc
NASDAQ:QTTB

Watchlist Manager
Homology Medicines Inc Logo
Homology Medicines Inc
NASDAQ:QTTB
Watchlist
Price: 1.875 USD 1.35% Market Closed
Market Cap: 22.9m USD

EV/EBIT
Enterprise Value to EBIT

0.5
Current
-6.3
Median
5.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
0.5
=
Enterprise Value
-34.9m USD
/
EBIT
-64.2m USD
EBIT Growth EV/EBIT to Growth
US
Homology Medicines Inc
NASDAQ:QTTB
Average EV/EBIT: 16.1
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 898.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
28%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.7
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
17%
1.3
AU
CSL Ltd
ASX:CSL
19.1
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
10%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
0.6
2-Years Forward
EV/EBIT
0.3
3-Years Forward
EV/EBIT
0.3